Galapagos To Present New Data At Ash 2023 From Ongoing CD19 Car-t Studies With GLPG5201 And GLPG5101

Author: Charles Gross | December 09, 2023 04:13pm

Galapagos NV ((Euronext &, NASDAQ:GLPG) to present additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December.

• Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancers
• Two poster presentations include recent data updates and additional data not included in the ASH abstracts

Posted In: GLPG